237 related articles for article (PubMed ID: 21228331)
1. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
2. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C; Towns WH; Chen CS; Goldenberg DM; Blum KA; Byrd JC; Muthusamy N; Praetorius-Ibba M; Baiocchi RA
Blood; 2011 Dec; 118(26):6893-903. PubMed ID: 22042694
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
4. Novel targeted therapies for mantle cell lymphoma.
Alinari L; Christian B; Baiocchi RA
Oncotarget; 2012 Feb; 3(2):203-11. PubMed ID: 22361516
[TBL] [Abstract][Full Text] [Related]
5. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Montraveta A; Xargay-Torrent S; López-Guerra M; Rosich L; Pérez-Galán P; Salaverria I; Beà S; Kalko SG; de Frias M; Campàs C; Roué G; Colomer D
Oncotarget; 2014 Feb; 5(3):726-39. PubMed ID: 24519895
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
8. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
9. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
10. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Alduaij W; Ivanov A; Honeychurch J; Cheadle EJ; Potluri S; Lim SH; Shimada K; Chan CH; Tutt A; Beers SA; Glennie MJ; Cragg MS; Illidge TM
Blood; 2011 Apr; 117(17):4519-29. PubMed ID: 21378274
[TBL] [Abstract][Full Text] [Related]
11. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.
Hertlein E; Triantafillou G; Sass EJ; Hessler JD; Zhang X; Jarjoura D; Lucas DM; Muthusamy N; Goldenberg DM; Lee RJ; Byrd JC
Blood; 2010 Oct; 116(14):2554-8. PubMed ID: 20574049
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
13. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
[TBL] [Abstract][Full Text] [Related]
14. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
15. FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?
Alinari L; Baiocchi RA; Praetorius-Ibba M
Autophagy; 2012 Mar; 8(3):416-7. PubMed ID: 22377620
[TBL] [Abstract][Full Text] [Related]
16. Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.
Singh V; Gupta D; Arora R; Tripathi RP; Almasan A; Macklis RM
PLoS One; 2014; 9(11):e111113. PubMed ID: 25364827
[TBL] [Abstract][Full Text] [Related]
17. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
[TBL] [Abstract][Full Text] [Related]
18. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
Lim SH; Vaughan AT; Ashton-Key M; Williams EL; Dixon SV; Chan HT; Beers SA; French RR; Cox KL; Davies AJ; Potter KN; Mockridge CI; Oscier DG; Johnson PW; Cragg MS; Glennie MJ
Blood; 2011 Sep; 118(9):2530-40. PubMed ID: 21768293
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. Milatuzumab - a promising new immunotherapeutic agent.
Berkova Z; Tao RH; Samaniego F
Expert Opin Investig Drugs; 2010 Jan; 19(1):141-9. PubMed ID: 19968579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
